- Business Wire•2 days agoData Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE® and ALPROLIX® Highlighted at 58th ASH Meeting
Biogen and Swedish Orphan Biovitrum AB will present new data, including updated longitudinal safety and efficacy findings from phase 3 and extension studies, on the companies’ extended half-life therapies, ELOCTATE® for hemophilia A and ALPROLIX® for hemophilia B, at the 58th American Society of Hematology Annual ...
- MarketWatch•10 days ago
European stocks closed higher Friday, a move that solidified a rise for blue-chip equities for a third consecutive week.
- Business Wire•14 days ago
Swedish Orphan Biovitrum AB today announces that the Ministry of Health in Kuwait has approved Elocta® , a recombinant human factor VIII Fc-fusion protein with an extended half-life, for the treatment of haemophilia A.
SOBI.ST : Summary for Swedish Orphan Biovitrum AB - Yahoo Finance
Swedish Orphan Biovitrum AB (SOBI.ST)
Stockholm - Stockholm Delayed Price. Currency in SEK
Add to watchlist
|Day's Range||96.10 - 97.90|
|52 Week Range||89.50 - 136.70|
|PE Ratio (TTM)||37.43|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|